eClinical Technology

Anticipating the Future: A Guide to Smart eClinical Technology Investments

04/28/2023

The landscape of clinical research is constantly evolving, and businesses need to keep up with the latest technology to remain competitive. However, investing in eClinical technology is not just about finding a solution for current needs, it’s equally important to think ahead and ensure that your technology investment can adapt and scale to meet future…

Read More

Decisions, Decisions! 3 good questions to ask when considering new eClinical Technology.

03/08/2023

For 2023, we’re taking our blog in a new direction with more content directly from our team, more detailed information for our readers answering common questions we get, and helpful expert information and ideas you can use. We hope you enjoy this new approach. For this week, we’re covering an introduction (or refresher) to TrialStat…

Read More

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy

11/16/2022

— Polymer-conjugated IL-15 (NKTR-255) induced CD8+ T cell and natural killer cell proliferation in vivo — — NKTR-255 enhanced the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model — Excerpt from the Press Release: SAN FRANCISCO, Nov. 9, 2022 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data…

Read More

RSIP Vision Presents Successful Preliminary Results from Clinical Study of 2D-to-3D Knee Bones Reconstruction

11/02/2022

A tool for reconstruction of a 3D model of the knee from 2D X-ray images is being evaluated on clinical data at a leading medical center with promising results Excerpt from the Press Release: TEL AVIV, Israel and SAN JOSE, Calif., Oct. 27, 2022 /PRNewswire/ — RSIP Vision, an experienced developer of groundbreaking AI technologies for…

Read More

Efemoral Medical Awarded Phase II SBIR Grant from NIH to Advance Treatment for Peripheral Artery Disease

09/28/2022

Excerpt from the Press Release: LOS ALTOS, Calif., Sept. 22, 2022 /PRNewswire/ — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Institutes of Health. SBIR grants are intended to stimulate technological innovation and encourage small United…

Read More

Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

08/29/2022

Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients Excerpt from the Press Release: MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing…

Read More

Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

07/07/2022

Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) – Oncology Pharma, Inc. (“The Company”) is pleased to be reviewing the financing for taking the steps on moving forward with its development process of. the Nanoemulsuion Drug Delivery System. Many anticancer drugs have been…

Read More

Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer

07/06/2022

Treatment with epigenomic controller, OTX-2002, resulted in robust in vivo efficacy in xenograft tumor models OTX-2002 successfully achieved pre-transcriptional downregulation of hepatocyte MYC gene expression in non-human primates Clinical potential of OTX-2002 as a monotherapy or in combination with existing standard-of-care therapies, including immune checkpoint inhibitors IND filed by the company to advance OTX-2002 into…

Read More

Proof Diagnostics Submits Request For Emergency Use Authorization Seeking First Approval Of Crispr-based Molecular Point-of-care Covid-19 Test

04/14/2022

If authorized by the FDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for COVID-19 (SARS-CoV-2) in as little as 18 minutes Excerpt from the Press Release: CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ — Proof Diagnostics, Inc., an innovative healthcare technology company delivering innovative solutions in molecular diagnostics, today announced the submission…

Read More

Exo® Announces Mobile-First, Secure Cloud-Based Point-of-Care Ultrasound Workflow Solution

03/18/2022

The device-agnostic software seamlessly integrates with hospital IT for streamlined documentation, billing and QA management all in one platform Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Exo (pronounced “echo”), a pioneering health information and devices company, has unveiled Exo Works™, an intelligent and intuitive point-of-care ultrasound workflow solution that enables physicians to easily document, review,…

Read More